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1933of the SCD equation because death did not actually occur.
Marathon race directors have adopted this approach (6), which
has had useful practical application in advising risk of participa-
tion, while assisting in event preparation and the best allocation of
limited resources.*Christine E. Lawless, MD, MBA
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Metoprolol,
But Which Metoprolol?
Effect on Inappropriate
Cardioverter-Deﬁbrillator TherapyRuwald et al. (1) studied the beneﬁt of carvedilol versus meto-
prolol for inappropriate antitachycardia pacing (ATP), using
data from the MADIT-CRT (Multicenter Automatic Deﬁ-
brillator Implantation with Cardiac Resynchronization Ther-
apy) trial. In a following editorial comment, Raitt (2) discusses
further the issue of inappropriate ATP. What is most surprising
is that neither Ruwald et al. (1) nor Raitt (2) specify metoprolol
as the tartrate or the succinate form. This failure to indicate
the rapid- or delayed-release forms of the medication whenconcluding superiority in favor of carvedilol has to be of concern
to the reader. The major clinical trial of metoprolol, MERIT-
HF (Metoprolol CR/XL Randomised Intervention Trial in
Congestive Heart Failure), which showed a signiﬁcantly decreased
all-cause mortality in their heart failure patients, speciﬁcally used
metoprolol succinate (3). When carvedilol and metoprolol were
compared in the COMET (Carvedilol or Metoprolol European
Trial) using metoprolol tartrate (target dose, 50 mg twice daily)
versus carvedilol (target dose, 25 mg twice daily), the composite
endpoint of mortality and all-cause admissions was not signiﬁ-
cantly different for the 2 medications, although the authors
considered that there was a suggestion of carvedilol superiority (4).
Obviously, the comparator in the current papers under consider-
ation (1,2) ideally should have been the succinate form of meto-
prolol, as in MERIT-HF (3).*Thomas F. Whayne, Jr, MD, PhD
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